Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
job cuts
Fierce Pharma
Novo struggles to appease restless investors with new strategy
CEO Mike Doustdar acknowledged that the company’s leadership “have to convince” investors that “there is a bright future for Novo.”
James Waldron
,
Fraiser Kansteiner
Sep 21, 2026 10:50am
Fierce Pharma
Novartis telegraphs 130 job cuts in Switzerland
Sep 2, 2026 2:15pm
TScan axes 75% of staff to make room for solid tumor programs
Sep 2, 2026 10:46am
Fierce Pharma
Narcan maker Emergent axes top R&D post in sweeping restructuring
Aug 5, 2026 8:16pm
Novartis trims ‘select number’ of biomedical research roles
May 15, 2026 10:58am
After buyout, Gilead is laying off Arcellx staff on both coasts
May 5, 2026 3:12pm